Preclinical Medications Discovery and Abuse Liability Testing

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH NIDA

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N98026R00083_SB

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Classification Code

AN11

Additional Details
Set Aside

NONE

Place of Performance

UNITED STATES

SourceSAM
The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA), has issued a Small Business Sources Sought (SBSS) notice under procurement identifier 75N98026R00083_SB. This notice seeks to identify qualified small business entities capable of supporting the Preclinical Medications Discovery and Abuse Liability Testing Program. The primary objective is to assess the availability and technical capability of small businesses to fulfill a potential requirement for preclinical evaluation of pharmacotherapies for substance use disorders and abuse liability testing of new street drugs, medications, and potential medications in rodent models. The scope of this requirement centers on the Addiction Treatment Discovery Program (ATDP), which was established in 2005 by consolidating several NIDA initiatives focused on treatment discovery for cocaine, opiate, methamphetamine, smoking cessation, and marijuana dependence. The contract aims to continue this tradition of efficiency and flexibility, supporting both the discovery of medications for substance use disorders and the generation of abuse liability data to inform drug scheduling decisions under the Controlled Substances Act and relevant international treaties. The data generated will be utilized by NIDA’s Medications Development Program and provided to the Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA) as needed. Key requirements for capable organizations include demonstrated in-house expertise in conducting in vivo pharmacology studies in rodents and primates, specifically for evaluating potential pharmacotherapies and new drugs of abuse. Essential deliverables and activities include: 1. Performing intracranial self-stimulation (ICSS) procedures to assess compounds for hedonic effects and their influence on the rewarding properties of drugs of abuse or withdrawal states. 2. Conducting assays to evaluate compounds’ ability to mitigate withdrawal aversive states from chronic opioid and nicotine administration in rodents. 3. Assessing compounds’ effects on non-reinforced operant responding in rats, serving as behavioral selectivity controls for relapse models. 4. Providing dosing guidance protocols for compound evaluation. 5. Determining in vivo receptor activity of compounds in rats or mice. 6. Establishing and maintaining robust security protocols for handling blinded test compounds distributed by the Government, including secure receipt, storage, tracking, and monitoring. 7. Maintaining comprehensive logs of compound receipt, evaluation results, documentation, and laboratory notebooks. 8. Accommodating optional periods and increased quantities based on programmatic needs and budget availability. Organizations must possess or be able to obtain DEA registration for Schedule I-V substances to perform these tasks. Compliance with the NIH Guide for Care and Use of Laboratory Animals and the Public Health Service Policy on Humane Care and Use of Laboratory Animals is mandatory, including the ability to obtain and maintain Animal Welfare Assurances. The procurement is classified under NAICS code 541715 (Research and Development in the Physical, Engineering, and Life Sciences, except Nanotechnology and Biotechnology), with a size standard of 1,000 employees. The Product Service Code is AN11. There is currently no set-aside type specified, but the Government is seeking information to determine if a socioeconomic set-aside is feasible. Only small businesses under the applicable NAICS code should respond. Responses should include detailed capability statements outlining relevant experience, personnel qualifications, facility capabilities, and prior performance in similar projects. Organizations are encouraged to provide references, documentation of past contracts (government and commercial), awards, and any other information that demonstrates their ability to effectively and timely administer interrelated tasks. Interested parties must submit their responses electronically in Microsoft Word or Adobe PDF format, limited to 20 pages (excluding cover page, executive summary, and references). Submissions must include the Unique Entity Identifier (UEI), organization name, address, point of contact, and business size/type. All correspondence should reference announcement number 75N98026R00083_SB and be sent to Joshua T Lazarus at [email protected] by June 12, 2026, 5:00 PM Eastern Time. This notice is strictly for market research and information gathering; it does not constitute a solicitation or a commitment to award a contract. The Government will not reimburse any costs incurred in responding. Respondents should not submit proprietary, classified, confidential, or sensitive information, as the Government reserves the right to use any nonproprietary technical information in any resultant solicitation. For further information, interested parties may contact Joshua T Lazarus at 301-827-6923 or via email. The place of performance is within the United States, and the opportunity remains active as of the posting date. Additional details and updates can be found at the official SAM.gov listing: https://sam.gov/opp/b33fb9daea094f9cae35b599c9075d6b/view. This opportunity is well-suited for small businesses with established expertise in preclinical pharmacology, substance use disorder research, and compliance with federal regulations regarding controlled substances and animal welfare. Contractors should carefully review the requirements and ensure their capabilities align with the technical and administrative expectations outlined in the notice.